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We have previously reported that the hepatitis B virus X protein (HBx) activates nuclear factor of activated T cells (NF-AT),
a key regulator of the immune system, by a calcium/calcineurin-dependent pathway, involving dephosphorylation and nuclear
translocation of this transcription factor. In addition, we showed that HBx synergizes with potent calcium-mobilizing stimuli
to activate NF-AT-dependent transcription, suggesting that additional mechanisms might also be operative in the activation
of NF-AT by HBx. Here we demonstrate that HBx activates the NH2-terminal transcription activation domain (TAD) of NF-AT1
by a mechanism involving protein–protein interaction. Targeting of HBx to the nucleus did not affect its ability to induce the
transcriptional activity of NF-AT1. In contrast, mutations of HBx affecting its functional interaction with general transcription
factors abrogated the HBx-induced activity of NF-AT1. Together these results indicate that HBx may exert its function byINTRODUCTION
The human hepatitis B virus (HBV) is an enveloped
and noncytopathic virus that causes acute and chronic
hepatic injury. Persistent HBV infection is strongly asso-
ciated with the development of hepatocellular carcinoma
(HCC) (Ganem and Varmus, 1987). The infection by HBV
shows a marked hepatic tropism. In addition, some au-
thors have also suggested that this virus might also
infect cells of the immune system, which may constitute
a reservoir for HBV (Korba et al., 1986; Lamelin et al.,
1995; Laure et al., 1985; Lobbiani et al., 1990; Zeldis et al.,
1986). The HBV genome is composed of a partially dou-
ble-stranded DNA of 3.2 kb that contains four overlap-
ping genes: S/PreS, C/PreC, P, and X (Tiollais et al.,
1985). The X gene encodes a 17-kDa protein, termed
HBx, that is involved in multiple viral and cellular pro-
cesses, such as virus replication, viral and cellular gene
transcription, cell-cycle control and apoptosis, intercel-
lular adhesion, and cell migration (Lara-Pezzi et al.,
2001a,b,c; Murakami, 1999).
Although HBx does not bind directly to DNA, it trans-
activates transcription through multiple cis-acting ele-
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288ments including AP-1, AP-2, ATF/CREB, NF-B, C/EBP,
Egr1, Sp-1, STAT, and nuclear factor of activated T cells
(NF-AT) binding sites (Murakami, 1999). There are at
least two possible mechanisms by which HBx may acti-
vate gene expression. It has been shown that HBx inter-
acts in the nucleus with components of the basal tran-
scription machinery and with several transcription fac-
tors to enhance their binding and/or transcriptional
activities (Murakami, 1999). Thus, HBx may exert its ef-
fect by mimicking the cellular coactivator function. An-
other proposed mechanism for HBx trans-acting function
involves the activation of cytoplasmic signal transduction
pathways, leading to the induction of various transcrip-
tion factors such as AP-1, NF-B, NF-AT, STAT-1, and
probably others (Murakami, 1999). Since HBx has been
found to be localized in both the nucleus and the cyto-
plasm of transfected cells, this viral protein may modu-
late gene expression by distinct mechanisms depending
on its intracellular location (Murakami, 1999).
Although the involvement of HBx in the genesis and
progression of hepatocellular carcinomas has been ex-
tensively studied (Cromlish, 1996; Kim et al., 1991; Koike
et al., 1994; Paterlini et al., 1995; Slagle et al., 1996; Su et
al., 1998; Terradillos et al., 1997; Yen, 1996; Yu et al.,
1999), there is only limited information regarding the role
of this viral protein in triggering the intrahepatic inflam-
matory events. In this context, we and others have re-acting as a nuclear coactivator of NF-AT1. © 2002 Elsevier S
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ported that HBx up-regulates in hepatocytes the expres-
sion of various genes encoding immune and inflamma-cience (U
phocyt
tory mediators (Majano et al., 1998; Murakami, 1999). In
addition, we have demonstrated that HBx activates NF-
AT, a key regulator of the immune and inflammatory
responses, by a cyclosporin A-sensitive mechanism, in-
volving dephosphorylation and nuclear translocation of
this transcription factor (Lara-Pezzi et al., 1998a).
NF-AT is a family of transcription factors that includes
at least four structurally related proteins: NF-AT1 (NF-ATp
or NF-ATc2), NF-AT2 (NF-ATc or NF-ATc1), NF-AT3 (NF-
ATc4), and NF-AT4 (NF-ATc3 or NF-ATx). NF-AT proteins
are cytoplasmic and are activated by stimulation of cell-
surface receptors coupled to calcium mobilization and
also by calcium ionophores such as ionomycin. Calcium
mobilization activates the phosphatase calcineurin
which dephosphorylates NF-AT proteins, promoting their
nuclear translocation and functional activation (Crabtree,
1999; Rao et al., 1997). Calcineurin docks at a consensus
sequence located within the NF-AT regulatory domain,
which is conserved in all the members of the NF-AT
family and therefore, termed NF-AT homology region
(NHR). The activation of NF-AT by calcium signals can be
inhibited by the immunosuppressive drugs cyclosporin A
and FK506, which inhibit calcineurin activity (Crabtree,
1999; Rao et al., 1997). However, it has been shown that
in T lymphocytes these drugs also interfere with the
activation of other transcription factors such as AP-1 and
NF-B via inhibition of Jun N-terminal kinases (JNKs), and
IB kinase (IKK) complex (Kiani et al., 2000). In contrast,
it has been demonstrated that specific peptides that
interfere with docking of calcineurin at the NF-AT regu-
latory domain provide a more selective inhibition of
NF-AT than cyclosporin A (Aramburu et al., 1999).
NF-AT1 (also called NF-ATp or NF-ATc2) is the found-
ing member of the NF-AT family and is expressed in
several cells of the immune system, including T lympho-
cytes, NK cells, mast cells, and monocytes, as well as in
other nonimmune tissues (Ho et al., 1994; Rao et al.,
1997). In resting T lymphocytes, NF-AT1 is the only family
member that is expressed (Lyakh et al., 1997). The most
NH2-terminal 100 amino acids of NF-AT1 contain a strong
acidic transcription activation domain (TAD), not con-
served in the other family members (Rao et al., 1997),
which has been shown to interact with p300/CBP coac-
tivators (Garcı´a-Rodrı´guez and Rao, 1998). Adjacent to
the TAD are located the calcineurin-binding regulatory
domain and the DNA-binding domain (DBD), which are
conserved among the different members of the NF-AT
family (Rao et al., 1997).
Our previous studies have demonstrated that HBx in-
duces NF-AT-dependent transcription by a cyclosporin-
A-sensitive (calcineurin-dependent) mechanism involv-
ing dephosphorylation and nuclear translocation of NF-
AT. We have also shown that HBx is able to further
increase the activity of NF-AT enhancers stimulated with
PMA plus calcium ionophore, which already provide a
full stimulus for NF-AT activation, suggesting that a dis-
tinct mechanism might also be involved in the activation
of NF-AT-dependent transcription by HBx (Lara-Pezzi et
al., 1998a). In this article, we demonstrate that HBx in-
teracts with the NF-AT1-TAD and enhances its transcrip-
tional activity. Our results suggest that HBx exerts its
function, at least in part, by acting as a nuclear coacti-
vator of NF-AT1.
RESULTS
HBx synergizes with cellular activation to induce
NF-AT-dependent transcription in Jurkat cells
To analyze whether HBx was able to synergize with
cellular activation to induce NF-AT-dependent transcrip-
tion in T lymphocytes, where the mechanisms of NF-AT
activation have been well characterized (Rao et al., 1997),
Jurkat cells were cotransfected with the reporter plasmid
pNF-AT-Luc along with the HBx-expression plasmid pSV-
HBx or the control vector pSV-hygro. The transfected
cells were stimulated with PMA plus calcium ionophore
(hereafter PMAIo) to localize endogenous NF-AT pro-
teins to the nucleus. The expression of HBx exerted a
marked synergism with the mitogenic stimulation of the
NF-AT enhancer. Induction of six- to eightfold over the
effect of PMAIo was observed when HBx was ex-
pressed (Fig. 1A, left panel). To determine the specific
contribution of NF-AT in the activation of the NF-AT en-
hancer, the plasmid pGFP-VIVIT, encoding a specific
NF-AT inhibitor, was also included in the cotransfection
experiments. As shown in left panel of Fig. 1A, both the
induction by PMAIo and the synergistic activation by
HBx and PMAIo of pNF-AT-Luc were clearly prevented
in the presence of NF-AT-specific inhibitor. In contrast,
the induction of the control plasmid pNF-kB-Luc by
PMAIo or PMAIo plus HBx was not significantly af-
fected by the expression of this inhibitor (Fig. 1A, right
panel). To substantiate further the ability of HBx to syn-
ergize with PMAIo in the induction of NF-AT-dependent
transcription, Jurkat cells were cotransfected with pNF-
AT-Luc along with the NF-AT1 expression vector pEF-HA-
NF-AT1 and either pSV-HBx or pSV-hygro. To localize
endogenous and transfected NF-AT proteins to the nu-
cleus, the cells were treated with PMAIo. The overex-
pression of NF-AT1 induced the NF-AT enhancer activity
three- to fivefold over the effect of PMAIo. Interestingly,
when both NF-AT1 and HBx were coexpressed, a strong
induction of 30- to 35-fold was obtained (Fig. 1B). Given
that PMAIo had been shown to provide a full stimulus
for nuclear translocation and activation of NF-AT in T
cells (Rao et al., 1997), our results indicated that HBx
might activate the NF-AT-TAD, once this transcription
factor had targeted its recognition sequences.
HBx activates the NH2-terminal TAD of NF-AT1
To explore the mechanism involved in the synergistic
activation of NF-AT by HBx, a Gal4-derived reporter sys-
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tem was employed. Jurkat cells were cotransfected with
the chimeric vector pGal4-NF-AT1 (1–415), encoding the
Gal4 DBD fused to amino acids 1–415 of human NF-AT1
(Fig. 2A), or the parental vector pRSV-Gal4-DBD, along
with the reporter plasmid pGal4-Luc and either pSV-HBx
or pSV-hygro. As expected, HBx did not stimulate tran-
scription when cotransfected with the control plasmid
pGal4-DBD (Fig. 2B). In contrast, the transcription of
pGal4-Luc was induced up to 10-fold by HBx when co-
transfected with Gal4-NF-AT1 (1–415) expression vector
(Fig. 2B). The fusion protein Gal4-NF-AT1 (1–415) con-
tained the calcineurin-binding regulatory domain (Luo et
al., 1996b), thus to ensure that the transcriptional activa-
tion by HBx was not just due to nuclear translocation of
this chimeric protein, the cotransfection experiments
were also performed in the presence of PMAIo, which
provide a full stimulus for nuclear translocation and ac-
tivation of NF-AT1. As shown in Fig. 2B, treatment with
PMAIo clearly enhanced the Gal4-NF-AT1 (1–415)-me-
diated transcriptional activation of pGal4-Luc. In addition,
coexpression of HBx increased the transcriptional activ-
ity of Gal4-NF-AT1 (1–415) up to fivefold over the values
obtained with PMAIo. Similar results were obtained
when the cells were cotransfected with recombinant
FIG. 1. HBx synergizes with mitogenic stimuli to induce NF-AT-dependent transcription in T cells. Jurkat cells were cotransfected with 2 g
pNF-AT-Luc or pNF-B-Luc along with 2 g pSV-HBx or the control plasmid pSV-hygro. (A) Two micrograms of GFP or GFP-VIVIT expression plasmids,
or (B) 2 g of pEF-HA-NF-AT1 or control vector, were included in the transfection experiments. Treatment with PMA (10 ng/ml) plus calcium ionophore
(0.5 M) for 16 h was used to localize endogenous and transfected NF-AT proteins to the nucleus. The luciferase activities are represented as fold
induction over the expression of pNF-AT-Luc in the absence of any stimuli, and values shown represent the mean fold-induction (SE) of at least three
independent experiments.
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GST-HBx protein instead of HBx-expression vector (Fig.
2C), thus ruling out that the cooperative induction of
Gal4-NF-AT1 (1–415) activity was due to up-regulation of
HBx expression by PMAIo. To further confirm that HBx
was able to activate NF-AT1 function via induction of its
TAD, two Gal4-NF-AT1 constructs, lacking functional cal-
cineurin-binding regulatory domain, were employed (Fig.
2A). These constructs had been shown to be no longer
regulated by calcium signals (Luo et al., 1996b). The
transcriptional activities of the chimeric proteins Gal4-
NF-AT1 (1–171) and Gal4-NF-AT1 SS (145–258) were
clearly enhanced by HBx (Fig. 2D). In contrast, HBx did
not stimulate the nonactive Gal4-NF-AT1 (101–407) pro-
tein, in which the TAD had been deleted. Taken together,
FIG. 2. Activation of Gal4-NF-AT1 chimeric proteins by HBx. (A) Schematic representation of the different Gal4 fusion proteins used, containing
various NF-AT1 fragments. (B) Jurkat cells were cotransfected with 4 g of the reporter plasmid pGal4-Luc along with 2 g of either the expression
vector encoding the fusion protein Gal4-NF-AT1 (1–415) or the parental empty vector pRSV-Gal4-DBD, and with 2 g of the expression plasmids
pSV-HBx or pSV-hygro. Twenty-four hours after transfection cells were either left untreated or stimulated with PMA (10 ng/ml) and calcium ionophore
(0.5 M) for 16 h prior to luciferase assay. (C) Luciferase assay similar to that described in (B) except for including 0.5 g of the GST and GST-HBx
fusion proteins instead of the pSV-HBx or pSV-hygro expression plasmids. (D) Jurkat cells were cotransfected with 4 g of the reporter plasmid
pGal4-Luc along with 2 g of the expression vector encoding the fusion protein pGal4-NF-AT1 (1–415), pGal4-NF-AT1 SS (145–258), pGal4-NF-AT1
(1–171), pGal4-NF-AT1 (101–407), or the parental empty vector pRSV-Gal4-DBD, and with 2 g of the expression plasmids pSV-HBx or pSV-hygro. The
luciferase activities are represented as fold induction over the values obtained with pGal4-Luc and pRSV-Gal4-DBD in the absence of any stimuli.
Values shown in (B) and (C) represent the mean fold-induction (SE) of at least three independent experiments. A representative experiment is shown
in (D).
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these data indicated that HBx was able to activate the
NH2-terminal TAD of NF-AT1.
HBx interacts with NF-AT1
To analyze whether the activation of NF-AT1-TAD by
HBx was mediated by a mechanism involving protein–
protein interaction, a GST-based pull-down assay was
carried out. GST-HBx, but not GST, immobilized on glu-
tathione–sepharose resin, was able to interact with en-
dogenous NF-AT1 protein from Jurkat cells (Fig. 3A).
To confirm the in vivo interaction of these proteins,
HEK293T cells were cotransfected with plasmids ex-
pressing full-length HA-tagged NF-AT1, HBx-Flag, or
both, and cellular lysates were immunoprecipitated us-
ing anti-HA mAb and immunoblotted with anti-Flag mAb.
HBx-Flag was coprecipitated with HA-NF-AT1 only in
cells cotransfected with both plasmids (Fig. 3B).
To determine whether the interaction of HBx with NF-
AT1 was direct, GST-HBx fusion protein was employed to
pull-down in vitro translated NF-AT1 fragment spanning
amino acids 1–400. As shown in Fig. 3C, GST-HBx, but
not GST, interacted with in vitro translated NF-AT1 (1–
400), in the absence of cellular lysate, suggesting a
direct interaction between both proteins.
Identification of the amino acid sequences involved in
HBx-NF-AT1 interaction
To identify the region of NF-AT1 involved in this inter-
action, several HA-tagged C-terminal deletion mutants of
NF-AT1 were generated. These constructs were trans-
fected into the HEK293T cells, and cellular lysates were
employed in pull-down assays with the GST-HBx fusion
protein. As shown in Fig. 4A, deletion of C-terminal se-
quences up to amino acid 187 of NF-AT1 did not affect
the binding to GST-HBx. Interestingly, the construct con-
taining only the first 68 amino acids of NF-AT1 did not
show binding to GST-HBx, but this fragment appeared to
be unstable when expressed in HEK293T cells (Fig. 4A).
Thus, to test whether the sequence spanning amino
acids 1 to 68 was involved in the binding to HBx, the
fusion proteins GST-HA-NF-AT1 (1–57) and GST-HA-NF-
AT1 (1–68) were used in pull-down assays using cellular
lysates from HEK293T cells transfected with a plasmid
encoding HBx-Flag. The fusion protein GST-HA-NF-AT1
(1–68) was able to interact with HBx, whereas no asso-
ciation was observed when GST-HA-NF-AT1 (1–57) was
used (Fig. 4B). To further confirm that the first 57 amino
acids of NF-AT1 were not mediating the interaction with
HBx, the plasmids encoding HA-NF-AT1 (57–235) and
HA-NF-AT1 (1–235) were transfected into the HEK293T
cells, and cellular lysates were used in pull-down assays
with GST-HBx. These two NF-AT1-derived constructs
showed specific interaction with HBx (Fig. 4C). There-
fore, these results indicated that the region involved in
the interaction with HBx was located between amino
acids 57 and 68 of NF-AT1, located within the TAD
(Fig. 4D).
To determine the region of HBx involved in the inter-
action with NF-AT1, several deletion mutants of HBx
FIG. 3. HBx interacts with NF-AT1. (A) GST-HBx or GST proteins were
employed in pull-down assays using total cellular extracts from Jurkat
cells (5  106 cells per lane). Proteins were fractionated by SDS–PAGE
(10%) and transferred onto nitrocellulose membranes for Western blot
analysis using 67.1 anti-NF-AT1 antiserum. A total Jurkat cell lysate was
included as a control (106 cells) (top). Coomassie brilliant blue staining
showed 1/10 of the GST proteins used in the pull-down assay (bottom).
(B) In vivo binding of HBx and NF-AT1. Total cellular extracts (5  106
cells per lane) of HEK293T cells, transfected either with pEF-HA-NF-
AT1, pSLN-HBx-Flag, or both, were immunoprecipitated with 12CA5
anti-HA mAb. Immunoprecipitates were fractionated by SDS–PAGE
(15%) and transferred onto nitrocellulose membranes for Western blot
analysis using M2 anti-Flag mAb. Total cellular lysates (106 cells per
lane) were included as controls. (C) Direct interaction of HBx and
NF-AT1. GST-HBx or GST proteins were used in pull-down assays with
in vitro translated, 35S-labeled NF-AT1 (1–400) and 0.25 l of 35S-labeled
NF-AT1 (1–400) was run as a control in left lane (top). Coomassie
brilliant blue staining showed 1/10 of the GST proteins used in the
pull-down assay (bottom).
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fused to GST (Fig. 5A) were employed in pull-down as-
says using lysates from HEK293T cells transfected with
pEF-HA-NF-AT1. The fusion protein GST-HBx3D5 (1–50)
displayed low or no binding to NF-AT1, whereas the
constructs GST-HBx5D1 (51–154), GST-HBx5D4 (72–154),
and GST-HBxSM (110–143) showed a binding to NF-AT1
similar to full-length GST-HBx (Fig. 5B). Interestingly, the
HBx sequence involved in NF-AT1 interaction overlapped
the transcription factor IIB (TFIIB)-binding region (Lin et
al., 1997).
HBx-NF-AT1 interaction is not sufficient to mediate
the activation of NF-AT1-TAD
Mutation analysis of HBx has defined two separate
regions necessary for its trans-activation function (Arii et
al., 1992; Runkel et al., 1993), which overlap the se-
quences involved in the interaction of HBx with RPB5 and
with TFIIB, respectively (Cheong et al., 1995; Haviv et al.,
1996, 1998b; Lin et al., 1997). In addition, it has been
proposed that trimeric interaction between HBx, RPB5,
and TFIIB is required for HBx trans-activation (Lin et al.,
1997). To analyze the relevance of these functional re-
gions of HBx in the activation of NF-AT1-TAD, a series of
nested deletion mutants of HBx (Fig. 6) was cotrans-
fected into Jurkat cells along with the reporter plasmid
pGal4-Luc and with either pGal4-NF-AT1 SS (145–258)
or pGal4-DBD expression vectors. Deletion of the NH2-
terminal portion of HBx up to amino acid 51 (5D3, 5D1)
did not affect the activation of NF-AT1-TAD (Fig. 6). Fur-
ther removal of NH2-terminal sequences up to amino
acids 72 or 102 (5D4 and 5D2), affecting the binding to
RPB5, abolished the trans-activation function of HBx de-
spite containing the NF-AT1 and TFIIB interaction se-
quences (Lin et al., 1997) (Fig. 6). In a similar manner,
removal of C-terminal sequences of HBx, that contained,
at least in part, the binding sequences for TFIIB and
NF-AT1 (3D39, 3D99), resulted in loss of trans-activation
function of HBx (Fig. 6).
To further confirm that the interaction of HBx with
components of the basal transcription machinery was
FIG. 4. HBx interacts with the NH2-terminal NF-AT1-TAD. (A) GST-HBx was used in pull-down assays using total cellular extracts from HEK293T cells
(5  106 cells per lane) transfected with expression plasmids containing different HA-tagged regions of NF-AT1 or the empty vector (left panel). Total
cellular lysates (106 cells per lane) were used to check protein expression in transfectants (right panel). Proteins were fractionated by SDS–PAGE
(10%) and transferred onto nitrocellulose membranes for Western blot analysis using 12CA5 anti-HA mAb. Arrows indicate position of the four proteins
expressed. (B) GST-HA-NF-AT1 (1–57), GST-HA-NF-AT1 (1–68), or GST-HA (as negative control) were used in pull-down assays with total cellular
extracts from HEK293T cells transfected with pSLN-HBx-Flag. Proteins were fractionated by SDS–PAGE (15%) and transferred onto nitrocellulose
membranes for Western blot analysis using M2 anti-Flag mAb. Total cellular lysates were included as controls (top). Coomassie brilliant blue staining
showed 1/10 of the GST proteins used in the pull-down assay (bottom). (C) GST-HBx was used in pull-down assays using total cellular extracts from
HEK293T cells transfected with HA-tagged NF-AT1 expression plasmids containing either residues 1–235 or 57–235 of the NH2-terminal domain. Total
cellular lysates were used to check protein expression in transfectants. Proteins were fractionated by SDS–PAGE (10%) and transferred onto
nitrocellulose membranes for Western blot analysis using 12CA5 anti-HA mAb. Arrows indicate position of the two proteins expressed. (D) Schematic
representation of the NF-AT1 constructs employed and resume of the HBx-binding activity observed.
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necessary for activation of NF-AT1-TAD, substitution mu-
tants of HBx, affecting its functional interaction with
RPB5 (NLS-HBx-m93) (Lin et al., 1997) or TFIIB (NLS-HBx-
m138) (Haviv et al., 1998b), were generated. In addition,
to ensure that these mutations were affecting the nuclear
function of HBx and not other ascribed functions of HBx
(e.g., activation of cytoplasmic signal transduction path-
ways), wild-type and mutated HBx proteins fused to a
nuclear localization sequence (NLS), which targeted HBx
to the nucleus (Doria et al., 1995) (data not shown), were
employed. These constructs were cotransfected into
Jurkat cells along with the reporter plasmid pGal4-Luc
and with either pGal4-NF-AT1 SS (145–258) or pGal4-
DBD expression vectors. Nuclear targeting of HBx did
not affect its ability to activate the NF-AT1-TAD (Fig. 7A).
However, mutations of HBx within the RPB5 (NLS-HBx-
m93) or TFIIB (NLS-HBx-m138) binding sequences abro-
gated the coactivation function of HBx on NF-AT1-TAD
(Fig. 7A). In a similar manner, these HBx mutants were
unable to synergize with PMAIo to activate the tran-
scriptional activity of pNF-AT-Luc (Fig. 7B). The differ-
ences in trans-activation activities of these HBx-derived
constructs were not due to different expression levels or
binding abilities to NF-AT1 as evidenced by Western
blotting and GST-based pull-down assays (Fig. 7C).
Taken together, these results demonstrate that activation
of NF-AT1 transcriptional activity by HBx not only re-
quires HBx-NF-AT1 interaction but also the binding of
HBx with the components of the transcription machinery.
DISCUSSION
Chronic infection of the liver by HBV leads to dramatic
changes of hepatocyte physiology, including the up-reg-
ulation of molecules that normally are not expressed, or
expressed at very low levels, some of which are key
immune and inflammatory mediators (Chisari and Fer-
rari, 1995). In this context, we and others have demon-
strated that human hepatocytes infected by HBV have
up-regulated expression, both in vivo and in vitro, of
TNF-, TGF-, Class I and II major histocompatibility
complexes, ICAM-1, and nitric oxide synthase 2-encod-
ing genes (Castilla et al., 1991; Franco et al., 1988; Gonza´-
FIG. 5. NF-AT1 interacts with the C-terminal region of HBx. (A)
Schematic representation of the GST-HBx constructs employed in the
pull-down assays. (B) Total cellular extracts from HEK293T cells trans-
fected with pEF-HA-NF-AT1 were used in pull-down assays with differ-
ent deletion mutants of HBx fused to GST. Proteins were fractionated by
SDS–PAGE (10%) and transferred onto nitrocellulose membranes for
Western blot analysis using 12CA5 anti-HA mAb. Total cellular lysates
were included as controls (top). Coomassie brilliant blue staining
showed 1/10 of the GST proteins used in the pull-down assay (bottom).
FIG. 6. Activation of NF-AT1-TAD by HBx deletion mutants. Schematic representation of the expression vectors employed encoding different
N-terminal or C-terminal deletion-mutants of HBx. Jurkat cells were cotransfected with 4 g of pGal4-Luc along with 2 g of either pGal4-NF-AT1 SS
(145–258) or the parental vector pRSV-Gal4-DBD, and with 2 g of each HBx expression plasmid or the control vector pSG5UTPL. The ability of each
HBx mutant to activate Gal4-NF-AT1 SS (145–258) is indicated by plus or minus.
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lez-Amaro et al., 1994; Majano et al., 1998; Montan˜o et al.,
1982; Volpes et al., 1990). It has been shown that the
expression of these and other inflammatory molecules
can be transcriptionally up-regulated by the HBV trans-
activator HBx (Hu et al., 1990, 1992; Lara-Pezzi et al.,
1998b; Lee et al., 1998; Mahe´ et al., 1991; Majano et al.,
1998; Yoo et al., 1996; Zhou et al., 1990). In this regard, we
have reported that HBx induces the transcriptional activ-
ity of TNF- promoter region through NF-AT-responsive
elements (Lara-Pezzi et al., 1998b). Furthermore, al-
though HBV has a marked hepatic tropism, it has been
suggested that this virus might also be able to infect
cells of the immune system (Korba et al., 1986; Lamelin et
al., 1995; Laure et al., 1985; Lobbiani et al., 1990; Zeldis et
FIG. 7. HBx induces NF-AT1 transcriptional activity by acting as a nuclear coactivator. (A) Jurkat cells were cotransfected with 4 g of pGal4-Luc
along with 2 g of either pGal4-NF-AT1 SS (145–258) or the parental vector pRSV-Gal4-DBD, and with 2 g of either the expression plasmids
pNLS-HBx-Flag, pNLS-HBx-Flag m93, pNLS-HBx-Flag m138, or control vector. In HBxm138 amino acid residues 138–140 (Arg-His-Lys), located within
the TFIIB-interaction region, were changed to Ala-Ala-Ala. In HBxm93 amino acids 93–96 (Leu-His-Lys-Arg) were substituted by Gly-Ala-Gly-Ala, which
interfere with the binding of HBx to RPB5. The luciferase activities are represented as fold induction over the values obtained with pGal4-Luc and
pRSV-Gal4-DBD. Values shown represent the mean fold-induction (SE) of at least three independent experiments. (B) Jurkat cells were cotransfected
with 2 g of pNF-AT-Luc along with 2 g of either the expression plasmids pNLS-HBx-Flag, pNLS-HBx-Flag m93, pNLS-HBx-Flag m138, or control
vector. Twenty-four hours after transfection cells were either left untreated or stimulated with PMA (10 ng/ml) and calcium ionophore (0.5 M) for 16 h
prior to luciferase assay. The luciferase activities are represented as fold induction over the expression of pNF-AT-Luc in the absence of any stimuli.
Values shown represent the mean fold induction (SE) of at least three independent experiments. (C) GST-HA-NF-AT1 (1–68) was used in pull-down
assays with total cellular extracts from HEK293T transfectants expressing NLS-HBx-Flag, NLS-HBx-Flag m93, or NLS-HBx-Flag m138. Proteins were
fractionated by SDS–PAGE (15%) and transferred onto nitrocellulose membranes for Western blot analysis using M2 anti-Flag mAb (left panel). Total
cellular lysates were included as controls (right panel).
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al., 1986). Thus, it is conceivable that HBV may also
induce in these cells the expression of molecules in-
volved in the immune and inflammatory responses. In
agreement with this hypothesis, we have recently dem-
onstrated that HBx is able to induce in T lymphocytes the
replication and transcription of HIV-1 in synergy with Tat
protein and T cell activation signals, being involved the
NF-B/NF-AT and Sp1-binding sites of the HIV-1 long-
terminal repeat (Go´mez-Gonzalo et al., 2001).
Mechanistically, dephosphorylation of NF-AT by the
calcium/calmodulin-dependent phosphatase calcineurin,
which leads to nuclear translocation of this transcription
factor, appears to be the major activation pathway of
NF-AT, at least in cells of the immune system (Crabtree,
1999; Rao et al., 1997). Our previous studies have evi-
denced that HBx is able to induce NF-AT-dependent
transcription by a mechanism involving calcineurin de-
regulation, leading to dephosphorylation and nuclear
translocation of NF-AT (Lara-Pezzi et al., 1998a). Interest-
ingly, we also observed that HBx is able to further en-
hance the activity of NF-AT-reporter plasmids stimulated
with PMA plus calcium ionophore, which already provide
a full stimulus for NF-AT activation. These results sug-
gested that a distinct mechanism might also function in
the activation of NF-AT-dependent transcription by HBx.
In this work, we have performed functional analysis in
the T lymphocyte derived cell line Jurkat, where the
activation processes of NF-AT have been extensively
studied. We have demonstrated that HBx induces the
transcriptional activity of the acidic NF-AT1-TAD once this
transcription factor has been targeted to its recognition
sequences in the nucleus, either by mitogenic stimula-
tion or by deletion of its calcineurin-binding regulatory
domain. These results are in good agreement with a
previous article which has shown that HBx preferentially
coactivates potent transcription factors, especially those
containing acidic transcription activation domains (Haviv
et al., 1995).
We have demonstrated, by coimmunoprecipitation and
GST-based pull-down assays, that HBx interacts directly
with NF-AT1. In addition, we have delimited the NF-AT1
site of interaction between amino acids 57 and 68, lo-
cated within the acidic TAD, which overlaps, at least in
part, the sequence involved in the interaction of NF-AT1
with the coactivators p300/CBP (Garcı´a-Rodrı´guez and
Rao, 1998). Interestingly, it has been recently reported
that HBx is able to overcome E1A-mediated suppression
of the transcriptional activity of Smads transcription fac-
tors, by stabilizing the formation of TFIIB/Smad complex
in the absence of p300/CBP (Lee et al., 2001). Thus, it can
be hypothesized that HBx could substitute for p300/CBP,
or other cellular coactivators such as the TBP-associated
factors (TAFs) (Haviv et al., 1996, 1998a), exerting similar
coactivator functions by interacting with basal transcrip-
tion machinery and with the NF-AT1-TAD. In this context,
we have shown that nuclear targeting of HBx does not
affect its ability to induce NF-AT1-TAD activity or to syn-
ergize with PMAIo in the activation of NF-AT-dependent
transcription. In contrast, deletion or substitution muta-
tions affecting the functional interaction of HBx with
either RPB5 or TFIIB, but not with NF-AT1, abrogate its
ability to induce NF-AT1 activity. Thus, the results pre-
sented herein together with our previous data indicate
that HBx may induce NF-AT-dependent transcription by
two different mechanisms, which involve dephosphory-
lation of cytoplasmic NF-AT and its nuclear import and,
on the other hand, functional activation of nuclear NF-
AT1 by interacting with its TAD.
There are controversial findings about the intracellular
localization of HBx. This viral protein has been shown to
have cytoplasmic (Sirma et al., 1998), nuclear (Haviv et
al., 1998b), and both cytoplasmic and nuclear localization
(Doria et al., 1995; Nomura et al., 1999). Recently it has
been shown that HBx is predominantly localized in the
nuclei in weakly expressing cells, whereas elevated cel-
lular HBx levels correlates with its accumulation in the
cytoplasm, suggesting that the capacity of HBx for nu-
clear compartmentalization is limited (Henkler et al.,
2001). Furthermore, it has been described that the inter-
action of HBx with either newly synthesized IB or
UV-damaged DNA-binding protein (UVDDB) may lead to
nuclear localization of HBx (Sitterlin et al., 2000; Weil et
al., 1999). Thus, the intracellular localization of HBx is not
unique and can be changed by its expression level and
by the cellular activation state. Depending on its major
intercellular localization, HBx may regulate transcription
by distinct mechanisms, as occurs with NF-AT-depen-
dent gene expression.
There are several other viral transcriptional activators
such as human immunodeficiency virus Tat and Nef
proteins, human T cell leukemia virus Tax protein, and
human hepatitis C virus core protein, that have been
shown to induce NF-AT-dependent transcription. While
Nef (Manninen et al., 2000; Wang et al., 2000), Tax (Good
et al., 1996, 1997), and core (Bergqvist and Rice, 2001)
proteins appear to induce NF-AT activity by a cytoplas-
mic pathway involving calcineurin deregulation, Tat pro-
tein up-regulates NF-AT transcriptional activity through a
mechanism that involves a direct interaction with the
amino-terminal domain of NF-AT1 (Macia´n and Rao,
1999). The results presented herein together with our
previous data indicate that HBx possesses a unique
feature among the viral transcriptional activators since it
may induce NF-AT-dependent transcription through both
cytoplasmic and nuclear mechanisms.
MATERIALS AND METHODS
Cell culture and reagents
Jurkat cells were grown at 37°C with a 5% CO2 atmo-
sphere in RPMI 1640 and HEK293T cells in Dulbecco’s
modified Eagle’s medium (DMEM), supplemented with
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10% fetal calf serum (FCS), 2 mM L-glutamine, and 50
g/ml gentamycin. Phorbol 12-myristate-13-acetate (PMA),
calcium ionophore A23187 (Io), and isopropyl--D-thio-
galactopyranoside (IPTG) were obtained from Sigma
Chemical Co. (St. Louis, CO).
Plasmid constructs
The expression vectors pSV-HBx and pSV-hygro, har-
boring the HBx open reading frame from HBV and the
bacterial hygromycin phosphotransferase gene, respec-
tively, under the control of the SV-40 promoter, have been
previously described (Chirillo et al., 1996). The expres-
sion vectors pNLS-HBx-Flag and pSLN-HBx-Flag, har-
boring a flag-tagged HBx open reading frame either with
a nuclear localization signal (NLS) or with a nonfunc-
tional mutated nuclear localization signal (SLN), respec-
tively, were kindly provided by Dr. R. J. Schneider (Kaplan
Cancer Center, New York, NY) and have been described
elsewhere (Doria et al., 1995). Substitution HBx mutants
m93 and m138 were generated by site-directed mu-
tagenesis (Stratagene, La Jolla, CA) using pNLS-HBx-
Flag as template. In HBxm93 amino acid residues 93–96
(Leu-His-Lys-Arg) were substituted by Gly-Ala-Gly-Ala,
which has been described to interfere with the binding of
HBx to the RNA polymerase subunit RPB5 (Lin et al.,
1997). In HBxm138 amino acid residues 138–140 (Arg-
His-Lys), located within the TFIIB-interaction region
(Haviv et al., 1996, 1998b; Lin et al., 1997), were changed
to Ala-Ala-Ala. The vectors pSG5UTPL-HBx wt, 5D1, 5D2,
5D3, 5D4, 3D5, 3D39, and 3D99, expressing either full-
length or truncated HBx proteins, were kindly provided
by Dr. S. Murakami (Cancer Research Institute, Ka-
nazawa, Japan) and have been described elsewhere
(Murakami et al., 1994). The plasmids encoding GST-HBx
full-length, GST-HBx 3D5 (aa 1–50), GST-HBx 5D1 (aa
51–154), and GST-HBx 5D4 (aa 72–143) were also pro-
vided by Dr. S. Murakami (Murakami et al., 1994). Plas-
mid pGST-HBx SM, encoding aa 110–143 of HBx, was a
kind gift from Dr. A. Siddiqui (University of Colorado,
Denver, CO) (Qadri et al., 1995), and pGST-ICAM3, in
which the cytoplasmic tail of the adhesion molecule
ICAM3 was fused to GST, was kindly provided by Dr. F.
Sa´nchez-Madrid (Hospital Universitario de la Princesa,
Madrid, Spain). The plasmids pRSVGal4-DBD, pGal4-NF-
AT1 (1–415), pGal4-NF-AT1 SS, and pGal4-NF-AT1 (1–
171) have already been described (Luo et al., 1996b). The
expression vector pGal4-NF-AT1 (101–407) was obtained
by cloning into pRSVGal4-DBD a PCR-generated frag-
ment which codes for amino acids 101–407 of human
NF-AT1. The reporter plasmid pGal4-Luc was a kind gift
from Dr. R. Perona (Instituto de Investigaciones Biome´di-
cas, Madrid, Spain) (Minden et al., 1995). The plasmid
pEF-HA-NF-AT1, encoding full-length HA-tagged murine
NF-AT1 under the control of elongation factor-1 pro-
moter, has been described elsewhere (Luo et al., 1996a).
The HA-tagged deletion mutants of murine NF-AT1 were
generated by PCR using pEF-HA-NF-AT1 as template
and cloned into the same expression vector. The expres-
sion vector used for in vitro synthesis of NF-AT1 was
generated by inserting a PCR fragment encoding amino
acids 1–400 of murine NF-AT1 under the control of the T7
promoter of pcDNA3.1 vector. The constructs pGST-HA,
pGST-HA-NF-AT1 (1–57), and pGST-HA-NF-AT (1–68)
were generated by PCR using pEF-HA-NF-AT1 as tem-
plate and cloning the fragments into pGEX-4T-2 (Amer-
sham Pharmacia Biotech, Uppsala, Sweden). The re-
porter construct pNF-AT-Luc contains three tandem cop-
ies of a composite NF-AT:AP-1 binding site of the human
IL-2 enhancer fused to the minimal IL-2 promoter and
was provided by Dr. G. Crabtree (Stanford University
Medical School, Stanford, CA) (Durand et al., 1988). The
reporter pNF-B-Luc, a kind gift from Dr. A. Israe¨l (Institut
Pasteur, Paris), contains a trimer of the NF-B motif of the
murine H-2Kb gene and has been previously described
(Yano et al., 1987). The expression plasmid pGFP-VIVIT,
harboring the highly specific NF-AT inhibitor VIVIT pep-
tide fused to the green fluorescence protein, was kindly
provided by Dr. Anjana Rao (Harvard Medical School,
Boston, MA) and has been described previously (Aram-
buru et al., 1999).
Transfection and luciferase assays
Jurkat cells were transfected with 2–4 g of reporter
vectors and either with 2 g of each expression plasmid
or with 0.5 g of GST-HBx fusion protein, employing
lipofectin (Gibco-BRL, Gaithersburg, MD). Twenty-four
hours after transfection cells were either left untreated or
stimulated with PMA (10 ng/ml) and calcium ionophore
(0.5 M) for 16 h. Then, cells were harvested and cellular
extracts were assayed for luciferase activity using a
Lumat LB9501 luminometer (Berthold, Wildbad, Germany).
Purification of recombinant proteins and pull-down
assays
GST fusion proteins were expressed in Escherichia
coli by induction with 0.1 mM IPTG at 30°C for 1 h. Cells
were harvested and lysed in EBC-DTT buffer (150 mM
NaCl, 50 mM Tris–HCl pH 8.0, 0.5% NP-40, 5 mM DTT, 1
g/ml aprotinin, 1 g/ml leupeptin, and 1 mM PMSF).
After centrifugation, supernatants were stored at 80°C.
For purification, the extracts were incubated with gluta-
thione-Sepharose 4B (Amersham Pharmacia Biotech) at
4°C for 30 min and then the beads were washed four
times with phosphate-buffered saline. Approximately 10
g of GST fusion proteins immobilized on glutathione-
Sepharose 4B were incubated with total cellular extracts
from Jurkat or transfected HEK293T cells in lysis buffer
containing 0.25% NP-40 at 4°C overnight. After being
washed four times with lysis buffer, bound proteins were
fractionated by SDS–PAGE, transferred onto nitrocellu-
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lose membranes, and subjected to Western blot analysis
using anti-NF-AT1 67.1 antiserum (Ho et al., 1994),
anti-HA 12CA5 mAb (Boehringer Mannheim, Mannheim,
Germany), or anti-Flag M2 mAb (Sigma Chemical Co.).
For direct interaction assays, GST-HBx or GST proteins
were incubated with 15 l of in vitro translated, 35S-
labeled murine NF-AT1 (1–400), which was synthesized
using TnT Coupled Reticulocyte Lysate Systems (Pro-
mega, Madison, WI). Binding was performed in binding
buffer containing 0.25% NP-40 for 2 h at 4°C. After wash-
ing, bound proteins were run in SDS–PAGE gel. Radio-
active signal was increased by incubating fixed gel with
Amplify reagent from Amersham Pharmacia Biotech and
directly visualized by autoradiography.
Coimmunoprecipitation
HEK293T cells, at 60% confluence, were cotransfected
with 5 g of each expression plasmid pEF-HA-NF-AT1
and pSLN-HBx-Flag, or the empty vectors, using the
FuGENE 6 transfection reagent (Boehringer Mannheim),
following manufacturer’s recommendations. Forty-eight
hours after transfection cells were lysed in buffer con-
taining 150 mM NaCl, 50 mM Tris–HCl pH 7.4, 0.25%
NP-40, 1 mM PMSF, 1 mM EGTA, 1 g/ml aprotinin, and
1 g/ml leupeptin, and precleared with protein A-Sepha-
rose (Pharmacia Biotech, Uppsala, Sweden). Precleared
lysates were then incubated with anti-HA mAb (12CA5)
for 2 h at 4°C, and with protein A-Sepharose for an
additional 2 h. Immunocomplexes were pelleted and
washed four times with lysis buffer. Bound proteins were
separated on a SDS–polyacrylamide gel and analyzed by
Western blotting using anti-Flag M2 mAb.
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